INTRODUCTION {#s1}
============

Gastric cancer (GC) is the fifth leading cause of cancer incidence and the third leading cause of cancer-related death after lung and liver cancer \[[@R1]\]. Multiple factors including molecular, genetic, and epigenetic changes as well as environmental factors (i.e., viral and bacterial infection) have been associated with the formation and progression of GC.

Cancer epigenetics comprise various fields, including DNA methylation, histone modifications, nucleosome positioning, and non-coding RNA. Among them, DNA methylation has long been studied as one of the important players during carcinogenesis, and promoter hypermethylation of several tumor suppressor genes (e.g., *p16*, *MLH1*, and *APC*) has been established as one of the key events. However, recent technological advances in genomic and epigenomic analyses have shown that distal regulatory regions such as enhancers are as important as proximal promoters in normal development and differentiation, and abnormal changes in the distal regulatory regions are associated with many diseases, including cancer. For example, Ziller et al. suggested that DNA methylation at enhancers is associated with key lineage specific regulators \[[@R2]\], and Aran et al. showed that methylation changes at distal regulatory sites were associated with gene expression in 58 cell types \[[@R3]\]. Additionally, long non-coding RNAs (lncRNAs) have drawn much interest as one of the important regulators during carcinogenesis and as potential biomarkers for early detection and prognosis and as predictive markers in multiple cancers \[[@R4]\].

Despite the growing interest in epigenomic changes at distal regulatory regions such as enhancers and lncRNAs, there have been few studies on the role of distal regulatory regions in GC. A few studies on DNA methylation in GC were performed with array-based DNA methylation profiling methods such as HumanMethylation27 and HumanMethylation450 BeadChip, with a focus on the proximal regulatory regions \[[@R5], [@R6]\]. To understand important epigenomic changes at the distal as well as proximal regulatory regions in GC compared with normal, we performed genome-wide methylation profiling using methyl-CpG binding domain sequencing (MBD-seq), H3K27ac ChIP-seq, and RNA-seq and performed integrated analyses of the epigenomic and transcriptomic data sets. Our results showed that the distal as well as the proximal regulatory regions are important during gastric carcinogenesis and should be studied further. Also, as recent TCGA work has shown that there are four distinct subtypes of GC showing different molecular patterns, we also investigated whether DNA methylation patterns change in a subtype-specific manner.

RESULTS {#s2}
=======

Genome-wide methylation profiling in GC {#s2_1}
---------------------------------------

We profiled DNA methylomes using five GCs and two normal tissues to identify differentially methylated regions (DMRs) between the two groups ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Approximately 0.1% (36,145 bins) of the hyper-methylated and 0.64% (221,506 bins) of the hypo-methylated DMRs (\|fc\| \>= 2 and P-value \< 0.05) were selected from a total of 34,496,773 bins (Figure [1A and 1B](#F1){ref-type="fig"}, [Supplementary Data S1](#SD2){ref-type="supplementary-material"}). On the whole, hypo-methylated regions were observed more frequently than hyper-methylated regions in GC, but hyper-methylated regions were more frequently observed in the 5′UTR, CGI and promoter areas than other regions (Figure [1C](#F1){ref-type="fig"}). Especially, lncRNAs in the 5′UTR and promoter regions (Gencode v. 19) were enriched with hypo-methylated DMR regions (Figure [1C](#F1){ref-type="fig"}). Most of the DMRs within the promoter, enhancer, and lncRNA regions were hyper-methylated in GC compared with the normal controls (Figure [1D, 1E, and 1F](#F1){ref-type="fig"}).

![Genome-wide identification of differentially methylated regions (DMRs) in GC compared with normal tissues\
**A.** A scatter plot of differentially methylated regions in GC (\|fc\| \> =2, and p-value \<= 0.05). **B.** A heat scatter plot of differentially methylated regions. **C.** Distribution of DMRs across various genomic features. **D, E, F.** MBD methylation levels at the promoter (D), enhancer (E), and non-coding regions (F) in GC compared with normal. Orange color represents cancer, and green color represents normal tissues.](oncotarget-07-25620-g001){#F1}

A few recent works showed that specific repetitive sequences (i.e. LINE-1) residing within some proto-oncogenes lead to the increased expression of oncogenes such as MET in colorectal cancer \[[@R7]-[@R9]\]. To identify over-expressed genes by hypomethylation at repetitive element in GC, we first selected 0.56% (3,128 regions) hypo-methylated repeat regions from a total of 5,298,130 repeat regions (University of California, Santa Cruz). Then the expression level of the closest gene was assessed for each hypo-methylated repeat. As a result, 574 over-expressed genes were chosen as candidates for hypomethylation at repeated elements ([Supplementary Data S2](#SD3){ref-type="supplementary-material"}). Among them, several genes including MCF21, FGFR3, RARA, MKRN2, AKAP13, VAV1, DACH1, and ZNF521 are known as oncogenes.

Detection of epigenetically regulated genes due to methylation at promoters as well as enhancers {#s2_2}
------------------------------------------------------------------------------------------------

To identify functionally relevant DMRs, mRNA-seq data were utilized for finding a strong negative correlation between gene expression and DNA methylation at the promoter, enhancer, and lncRNA regions (Figure [2A](#F2){ref-type="fig"}). In promoter regions, 140 hyper and 154 hypo-methylated genes were identified as having significant negative correlation with the expression of their corresponding genes (Figure [2B](#F2){ref-type="fig"} and [Supplementary Data S3](#SD4){ref-type="supplementary-material"}). Functional annotation of these genes showed that the under-expressed genes with promoter hypermethylation were enriched in GO terms such as 'MAPK signaling pathway' (P-value: 0.0026), 'Basal cell carcinoma' (P-value: 0.0071), and 'Hedgehog signaling pathway' (P-value: 0.0075) (Figure [2A](#F2){ref-type="fig"} and [Supplementary Table S2](#SD1){ref-type="supplementary-material"}). The over-expressed genes with promoter hypomethylation were enriched in terms such as 'maturity onset diabetes of the young (P-value: 5.68E-04)' and 'neuroactive ligand-receptor interactions (P-value: 0.08)' (Figure [2A](#F2){ref-type="fig"} and [Supplementary Table S3](#SD1){ref-type="supplementary-material"}).

![Integrated analysis of methylome and transcriptiome profiling in GC\
**A.** Matched heat map of gene expression and methylation profiling. **B, C, D.** Inverse correlation between methylation values of three regulatory regions and mRNA abundance. The scatter plot shows the correlation of gene expression and methylation at the promoter (B), enhancer (C), and non-coding regions (D). The blue line represents a linear regression. **E.** The methylation (upper) and expression (bottom) levels of hypo-methylated and up-regulated genes in GC compared with normal controls. The yellow and red box represents cancer samples, and the blue and green represents normal samples.](oncotarget-07-25620-g002){#F2}

To investigate the functional significance of epigenetic changes at the distal regulatory regions in GC, we examined DNase-seq data ([Supplementary Table S4](#SD1){ref-type="supplementary-material"}) in 11 gastric tissues and H3K27ac ChIP-seq data (cell lines and tissue samples for ChIP-seq are listed in Materials and Methods) in 7 GC cell lines. We defined 134,322 enhancers in gastric tissue by intersecting 227,413 peaks from DNase-seq and 363,256 peaks from H3K27ac ChIP-seq for gastric-specific active enhancers. Then, the expression level of the closest gene was assessed for each enhancer. As a result, 606 genes were identified to have a strong negative correlation between gene expression and the DNA methylation of their enhancer regions (Figure [2C](#F2){ref-type="fig"} and [Supplementary Data S4](#SD5){ref-type="supplementary-material"}). Among them, 433 genes over-expressed due to enhancer hypo-methylation were enriched in GO terms such as 'focal adhesion' (*VAV3, CCND2, COL6A2, COL6A1*, and *THBS2;* P-value: 0.030) and 'ECM-receptor interaction' (*GP6, COL6A2, COL6A1, COL1S1, THBS2*, and *COL5A1*; P-value: 0.0357) (Figure [2A](#F2){ref-type="fig"} and [Supplementary Table S5](#SD1){ref-type="supplementary-material"}). Furthermore, motif analysis using the Homer tool revealed that motifs of the TEAD family genes such as TEAD1, TEAD2, and TEAD4 were enriched at the hypo-methylated enhancer regions ([Supplementary Figure S1A](#SD1){ref-type="supplementary-material"}) \[[@R10]\]. As de-methylation at enhancers is often associated with the binding of transcription factors during carcinogenesis \[[@R11], [@R12]\], we investigated whether those hypo-methylated enhancers were bound by *TEAD4* by analyzing the previously published *TEAD4* ChIP-seq data in two gastric cancer cell lines \[[@R13]\]. From the ChIP-seq study, 483 peaks (247 genes) from the MKN28 cell line and 232 peaks (102 genes) from the SNU216 cell line were found to be *TEAD4*-enriched and to contain hypo-methylated enhancer regions, among which 86 genes were common between the two cell lines ([Supplementary Figure S1B](#SD1){ref-type="supplementary-material"}). Enrichment analysis with the common 86 genes revealed that terms such as 'cell adhesion molecules' (P-value: 5.50E-03) and 'pathway in cancer' (P-value: 4.80E-02) were highly enriched ([Supplementary Table S6](#SD1){ref-type="supplementary-material"}) \[[@R14], [@R15]\]. Among these, the expression of *THBS2* and *CLDN15* showed a significant negative correlation with the methylation levels of *TEAD4*-enriched enhancers in GC compared with normal tissues (\|fc\| \>= 2 and P-value \< 0.05) ([Supplementary Figure S1C, Supplementary Figure S2A and S2D](#SD1){ref-type="supplementary-material"}). We validated the methylation and expression levels of THBS2 using TCGA data. *THBS2* was significantly over-expressed in 212 GCs compared with 28 normal samples from the TCGA cohorts (RNA-seq; [Supplementary Figure S2B](#SD1){ref-type="supplementary-material"}). We also investigated the methylation changes at the intergenic enhancer region of *THBS2* from the TCGA HumanMethylation 450 BeadChIP data and found that the *THBS2* enhancer region was significantly hypo-methylated in GC compared with normal tissues ([Supplementary Figure S2C](#SD1){ref-type="supplementary-material"}).

To investigate the potential of epigenetic change at gastric specific enhancers \[[@R16]\], we analyzed the recently published epigenome data from Roadmap Epigenomics Project (<http://www.roadmapepigenomics.org/>) including a few gastric samples ([Supplementary Table S7](#SD1){ref-type="supplementary-material"}). Among 216,695 gastric-specific enhancers, 7,826 (3.61%) were hyper-methylated, and 28,141 (12.99%) were hypo-methylated ([Supplementary Data S5](#SD6){ref-type="supplementary-material"}). In total, 4,911 genes were identified as closest gene at epigenetically changed enhancer regions. Among them, several genes were related in cancer pathway such as EGFR, RARA, FGF2, FGFR1, FGFR2, FGFR3, KIT, and CCND1.

Epigenetically regulated lncRNAs {#s2_3}
--------------------------------

LncRNAs, non-protein coding transcripts longer than 200 nucleotides, have emerged as one of the important players during gastric carcinogenesis, and many lncRNAs have been shown to be aberrantly expressed in GC. Hence, we investigated the role of DNA methylation in the aberrant expression of lncRNAs in GC. Among 20,019 lncRNAs (Gencode v. 19), 1,497 (7.47%) were hyper-methylated, and 4,027 (20.21%) were hypo-methylated ([Supplementary Figure S3A](#SD1){ref-type="supplementary-material"}). Among them, 1,130 (5.64%) hyper-methylated and 2,139 (10.68%) hypo-methylated regions overlapped with enhancer peaks defined by the DNase-seq and H3K27ac ChIP-seq data ([Supplementary Figure S3A](#SD1){ref-type="supplementary-material"}). Combined analyses of the RNA-seq and MBD-seq data revealed 41 lncRNAs under-expressed due to hypermethylation and 12 lncRNAs over-expressed due to hypomethylation (Figure [2A](#F2){ref-type="fig"}; [Supplementary Data S6](#SD7){ref-type="supplementary-material"}). Of these lnc-RNAs, the expression of *MALAT1*, *EVX-AS*, *SH3RF3-AS*, *RP-17-19.14* (reverse strand of *HOXA11-AS*), *HOXD-AS1*, and *HOXD-AS2* showed a significant negative correlation with the DNA methylation levels at the promoters of the lncRNAs (Figure [2D](#F2){ref-type="fig"}). Additionally, the *U47924.27* (Gencode identification) locus containing *MIR200C* and *MIR141* was found to be hypo-methylated at its promoter and over-expressed in GC (Figure [2A](#F2){ref-type="fig"}; [Supplementary Figure S3B](#SD1){ref-type="supplementary-material"}). *MALAT1* is known to be frequently over-expressed in human malignancies including GC \[[@R17]\], and [Supplementary Figure S4A](#SD1){ref-type="supplementary-material"} shows that *MALAT1* was significantly over-expressed in GC due to promoter hypo-methylation. We validated the methylation and expression levels of *MALAT1* using the TCGA cohort. Two of the eight probes located in the promoter of *MALAT1* were significantly hypo-methylated in GC according to data from the TCGA (HumanMethylation450k beadchip) ([Supplementary Figure S4B](#SD1){ref-type="supplementary-material"}). Additionally, the expression level of *MALAT1* in GC using the 240 RNA-sequencing data from the TCGA cohorts was assessed and showed that *MALAT1* was significantly over-expressed in GC compared with normal tissues ([Supplementary Figure S4C](#SD1){ref-type="supplementary-material"}). To verify whether 5-Aza-dC influences *MALAT1* expression, we treated four gastric cancer cell lines with 5-Aza-dC. The expression of *MALAT1* in the four gastric cancer cell lines (SNU620, SNU005, SNU016, and AGS) was increased by 5-Aza-dC treatment ([Supplementary Figure S4D](#SD1){ref-type="supplementary-material"}). This result indicates that changes in methylation at *MALAT1* promoter may contribute to the over-expression of *MALAT1* in GC.

Over-expression of *HNF4A* due to promoter hypo-methylation in GC compared with normal {#s2_4}
--------------------------------------------------------------------------------------

To identify novel epigenetically altered oncogenes, we focused on genes that are over-expressed due to promoter hypo-methylation. One of the epigenetically altered genes was *HNF4A*, known as a key member of the nuclear receptor subfamily of ligand-dependent receptors. Chang et al. recently showed that *HNF4A* is a novel therapeutic target that links AMPK to WNT signaling in early-stage gastric cancer \[[@R18]\]. Interestingly, two distinct promoters (HNF4A-P1 and HNF4A-P2) are known to increase the expression of *HNF4A* in some cancers. Thus, we examined the methylation of the two promoters and the expression level of *HNF4A* in GC tissues and cell lines (Figure [3A](#F3){ref-type="fig"}). *HNF4A* was significantly over-expressed in 212 GCs compared with 28 normal samples from the TCGA cohorts (Figure [3B](#F3){ref-type="fig"}). Additionally, the promoter methylation levels of HNF4A-P1 and HNF4A-P2 were confirmed using the HumanMethylation450k BeadChip array from the TCGA cohorts (Figure [3C](#F3){ref-type="fig"}) and were inversely correlated with their expression in GCs compared with normal controls. However, we found that both HNF4A-P1 and HNF-P2 were coordinately methylated in GC (Figure [3C](#F3){ref-type="fig"}). Hypomethylation of the *HNF4A* promoter region was independently validated using the MENT database ([Supplementary Figure S5A](#SD1){ref-type="supplementary-material"}) \[[@R19]\].

![Methylation profiling of *HNF4A* as a target for promoter hypo-methylation\
**A.** Screenshot of the IGV browser shows the promoter of *HNF4A.* Display tracks include the abundance of promoter methylation and expression. **B.** The expression levels of *HNF4A* in 240 gastric tissues from the TCGA cohorts (mRNA-seq). The red box represents cancer samples and the green box represents normal samples (\*: p-value \< 0.05; \*\*: p-value \< 0.005; \*\*\*: p-value \< 0.0005). **C.** The methylation levels of HNF4A-P1 (Top) and HNF4A-P2 (Bottom) in GC and normal tissues from the HumanMethylation450k BeadChip array. The yellow box represents cancer samples and the blue box represents normal samples (\*: p-value \< 0.05; \*\*: p-value \< 0.005; \*\*\*: p-value \< 0.0005). **D.** *HNF4A* over-expression by 5-Aza-dC in gastric cancer cell lines. Quantitative RT-PCR was performed using P1 and P2 specific primers for HNF4A. The red bar represents HNF4A-P1 and the green bar represents HNF4A-P2. **E.** Bisulfite sequencing result of CpG sites (n=12) in the HNF4A-P1 promoter region. **F.** Bisulfite sequencing result of CpG sites (n=21) in the HNF4A-P2 promoter region.](oncotarget-07-25620-g003){#F3}

To verify whether 5-Aza-dC, an inhibitor of the DNMT enzymes, influences *HNF4A* expression, we treated two gastric cell lines with 5-Aza-dC. We first performed quantitative RT-PCR to measure the expression levels of *HNF4A*-P1 and *HNF4A*-P2 in diverse gastric cancer cell lines and selected two cell lines (KATO-III and MNK1), which expressed HNF4A-P1 and HNF4A-P2 at low levels ([Supplementary Figure S5B and S5C](#SD1){ref-type="supplementary-material"}). The expression of *HNF4A* in KATO-III and MKN1 was augmented by 5-Aza-dC treatment (Figure [3D](#F3){ref-type="fig"}). This result indicates that changes in methylation at *HNF4A* promoters may contribute to the over-expression of *HNF4A* during the development of GC. We also performed bisulfite sequencing to measure the methylation levels of HNF4A-P1 (Figure [3E](#F3){ref-type="fig"}; P-value: 0.01) and HNF4A-P2 (Figure [3F](#F3){ref-type="fig"}; P-value: 0.16) in three pairs of GC and adjacent normal tissues. Both promoters of *HNF4A* were hypo-methylated in the GC tissues compared with the normal controls.

GC molecular subtype specific DMRs {#s2_5}
----------------------------------

A recent TCGA study on gastric cancer classified GC into four distinct molecular subtypes: CIN+, EBV+, GS+, and MSI+ \[[@R20]\]. Among them, the EBV+ and MSI+ subtypes are characterized by extensive DNA methylation. Subtype-specific DMRs were predicted using the TCGA stomach cancer (STAD) methylation and expression data, which comprise HumanMethylation450K for CIN+ (n=122), EBV+ (n=25), GS+ (n=52), MSI+ (n=49); six normal samples and RNA-seq data for CIN+ (n=101), EBV+ (n=19), GS+ (n=41), and MSI+ (n=41) gastric cancer; and 28 normal samples ([Supplementary Data S7](#SD8){ref-type="supplementary-material"}). Student\'s t-test was used to compare the samples from each subtype and normal group, and 379 hyper-methylated and under-expressed genes and 309 hypo-methylated and over-expressed genes were selected (Figure [4A](#F4){ref-type="fig"}; [Supplementary Data S8](#SD9){ref-type="supplementary-material"}). Among them, 355 genes were under-expressed due to subtype-specific hyper-methylation. Functional enrichment analysis revealed the enrichment of GO categories such as secretion (*FAM3B*, *CA9*, *GHRL*, *NMU*), digestion (*TFF3*, *GHRL*, *NMU*) and EBV-associated hyper-methylation (*BNIP3*, *FAM3B*, *FLNC*) (Figure [4A](#F4){ref-type="fig"}). Two examples of EBV+ specific genes, *FAM3B* and *FLNC*, were shown to exemplify the importance of subtype-specific analysis.

![Molecular subtype-specific methylation and expression profiling in GC\
**A.** Methylation and expression profiling of subtype-specific methylation targets. **B.** *FAM3B* promoter methylation (left) and mRNA expression (right) levels in GC and normal tissues from the TCGA cohorts. The yellow and red box indicates cancer samples and the blue and green box indicates normal samples. **C.** *FAM3B* promoter methylation (left) and mRNA expression (right) levels in the normal tissues, and the CIN+, EBV+, GS+, and MSI+ gastric tumor subtypes. **D.** *FLNC* promoter methylation (left) and mRNA expression (right) levels in GC and normal tissues from the TCGA cohorts. The yellow and red box indicates cancer samples and the blue and green box indicates normal samples. **E.** *FLNC* promoter methylation (left) and mRNA expression (right) levels in the normal tissues, and the CIN+, EBV+, GS+, and MSI+ gastric tumor subtypes.](oncotarget-07-25620-g004){#F4}

For *FAM3B*, the difference in methylation between the cancer and normal groups was insignificant, although a subset of samples showed a distinct pattern of hyper-methylation (Figure [4B](#F4){ref-type="fig"}, left panel). On the contrary, the difference in expression between the cancer and normal groups was significant (Figure [4B](#F4){ref-type="fig"}, right panel). Subtype-specific analysis revealed that only the EBV+ subtype GCs showed hyper-methylation of *FAM3B* (Figure [4C](#F4){ref-type="fig"}, left panel), while the other subtype GCs had similar methylation patterns to the normal group. The EBV+ subtype GCs showed the most decreased expression of *FAM3B* (Figure [4C](#F4){ref-type="fig"}, right panel), but the other subtype GCs also showed modest under-expression of *FAM3B* compared with the normal groups, suggesting that the mechanism of *FAM3B* under-expression is distinct from DNA methylation. Thus, subtype specific analysis clearly showed that the EBV+ subtype and the other subtypes had a distinct mechanism of *FAM3B* under-expression in GC. For *FLNC*, differences in both methylation and expression between the GC and normal groups were insignificant (Figure [4D](#F4){ref-type="fig"}). However, subtype-specific analysis again revealed that *FLNC* was under-expressed due to hyper-methylation in the EBV+ subtype alone (Figure [4E](#F4){ref-type="fig"}).

DISCUSSION {#s3}
==========

Several groups have previously reported genome-wide DNA methylation changes in GC using chip-based methods or MIRA-seq technology. Zouridis et al. generated methylation profiles of 240 GCs and 94 matched normal samples using the HumanMethylation27k array \[[@R21]\]. The TCGA consortium recently reported the methylation profiling of 295 GCs using the HumanMethylation450k array \[[@R20]\]. Park et al. used MIRA-seq to characterize genome-wide methylation patterns at CpG rich regions and repeat regions using three GC and matched normal samples \[[@R22]\]. Muratani et al. reported chromatin alteration at the promoters and predicted enhancers focusing on histone modifications in primary gastric cancer in multiple ChIP-seq datasets \[[@R23]\]. However, the above-mentioned studies focused mainly on the proximal regions using array platforms which does not cover the potentially important distal regulatory regions, due to the limitation of the array probe design. In contrast, our study assessed genome-wide DNA methylation changes not only at the proximal regions but also at the distal regulatory elements in GC.

By combining MBD-seq with H3K27ac ChIP-seq and DNase-seq, we identified a large number of gastric enhancers with DNA methylation changes. We further showed that hypo-methylated-enhancer sites were enriched with the *TEAD4* motif, some of which were bound by *TEAD4*, leading to increases in the expression of their respective genes ([Supplementary Figure S1C](#SD1){ref-type="supplementary-material"}). *THBS2* has been implicated as a modulator of cell surface properties that are involved in cell adhesion and migration \[[@R24], [@R25]\]. The expression of *THBS2* was significantly increased in colon, esophagus, lung, and stomach cancers as analyzed using the GENT database ([Supplementary Figure S6A](#SD1){ref-type="supplementary-material"}) \[[@R26]\]. Notably, we found that *THBS2* was over-expressed due to de-methylation at its enhancer containing *TEAD4* binding sites ([Supplementary Figure S2A](#SD1){ref-type="supplementary-material"}). We also investigated the methylation changes at the intergenic enhancer region of *THBS2* in various cancers from the TCGA data (HumanMethylation450 BeadChIP) and found that the enhancer of *THBS2* was significantly hypo-methylated in colon and liver cancers ([Supplementary Figure S6B and S6D](#SD1){ref-type="supplementary-material"}) but not in kidney and pancreatic cancers ([Supplementary Figure S6C and S6E](#SD1){ref-type="supplementary-material"}). These results indicate that DNA methylation changes at the distal enhancers occur in a tissue-specific manner.

Integrated analysis of promoter methylation and expression revealed many potential epi-driver genes including *MUC6*, *MUC4*, *CDX1*, *HNF4A*, MAGE family genes (*MAGEA1*, *MAGEA6*, *MAGEC1*, and *MAGEC2*), which were hypo-methylated at their promoters and were over-expressed (Figure [2E](#F2){ref-type="fig"}). Further studies are needed to evaluate whether the above mentioned genes have oncogenic activity. Among them, expression of *HNF4A* is increased by alternative promoters in several cancers such as liver, gastric, and colorectal cancers \[[@R27]\]. Hence, we investigated whether the two promoters of HNF4A (HNF4A-P1 and HNF4A-P2) were differentially methylated. But, our result indicates that HNF4A expression was increased by simultaneous de-methylation of the two promoters (Figure [3](#F3){ref-type="fig"}). Similarly, both promoters of *HNF4A* were significantly hypo-methylated in liver and colon cancers ([Supplementary Figure S7A, and S7B](#SD1){ref-type="supplementary-material"}). On the other hand, in pancreatic cancer, only P1-promoter was significantly hypo-methylated without P2-promoter hypo-methylation ([Supplementary Figure S7C](#SD1){ref-type="supplementary-material"}). Thus, we conclude that DNA methylation may play an important role by switching the active promoter of *HNF4A* in a tissue-specific manner.

As another example of epigenetic regulation, we analyzed methylation changes at the promoter regions of lncRNAs and identified putative lncRNAs such as *MALAT1*, *HOXD-AS1*, *HOXD-AS2*, and *EBV1-AS* (Figure [2A](#F2){ref-type="fig"}). Over-expression of *MALAT1* is frequently detected in human malignancies including GC, and it has been suggested as an oncogene \[[@R28]-[@R30]\]. We discovered that promoter de-methylation of MALAT1 could be a major mechanism for its over-expression in GC ([Supplementary Figure S4](#SD1){ref-type="supplementary-material"}).

We characterized subtype-specific methylation changes in GC for each of the four subtypes (CIN+, EBV+, GS+, and MSI+) by analyzing the HumanMethylation450k data. As previously reported \[[@R20]\], the EBV+ subtype was overwhelmingly hyper-methylated compared with the other molecular subtypes (Figure [4A](#F4){ref-type="fig"}). Several genes including *FAM3B* and *FLNC* were identified as hyper-methylated in the EBV+ subtype by subtype specific-analysis (Figure [4B, 4C, 4D, and 4E](#F4){ref-type="fig"}) \[[@R31], [@R32]\].

In conclusion, we highlight the importance of DNA methylation marks at the distal regulatory regions and lncRNAs as well as the proximal promoters in GC. Many DMRs were identified at the distal regulatory regions in GC and may have functional roles in the epigenetic regulation of gene expression.

MATERIALS AND METHODS {#s4}
=====================

Cell lines and tissue samples {#s4_1}
-----------------------------

Seven gastric cancer cell lines (AGS, MKN1, MKN45, SNU719, SNU016, KATOIII, and SNU638) were obtained from the Korean Cell Line Bank (<http://cellbank.snu.ac.kr/english/index.php>) and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic solution (Invitrogen, Carlsbad, CA). Paired gastric tumor and adjacent non-cancerous gastric mucosae samples were collected from the Pusan National University Yangsan Hospital. The study protocol was approved by the institutional review board of the hospital.

MBD-seq and data analysis {#s4_2}
-------------------------

MBD2-immunoprecipitated chromatin fragments were collected and 200\~300-bp size-selected genomic libraries were prepared from DNA samples using the TruSeq ChIP Sample Prep Kit (Illumina). The libraries were multiplexed and sequenced on the Illumina platforms (GA IIx or Hiseq-2000). After sequencing, single-end reads (51 bp or 76 bp) were aligned against the human reference genome 19 with the BWA aligner \[[@R33]\]. The MEDIPS R package (v. 1.18.0) was used for the analysis of MBD-seq data and DMR identification \[[@R34]\]. The Homer (v.4.7) software was used for the annotation of peaks and assessment of the distribution of methylation peaks across genomic features \[[@R10]\]. Genomic features were classified into six regions: intergenic, 5 UTR, 3 UTR, promoter, CDS, and intron, based on the UCSC genome annotation information. For the locations related to a CGI (CpG island), we used three groups: within CGI, in CGI shore (2 kb region from the CGI), and non-CGI. All the MBD sequencing data were submitted to the public repository (GEO Accession Number: GSE46595). Bam files were available at <http://mgrc.kribb.re.kr/KRIBB/BAM/MBD-seq/MBD-seq.html>.

RNA-seq and data analysis {#s4_3}
-------------------------

The RNA sequencing library was prepared using the TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA, USA) and sequenced using Genome Analyzer IIx (Illumina) or Hiseq-2000 (Illumina) to generate 76 or 101-bp paired end reads. The sequenced reads were mapped to the human genome (hg19) using TopHat 2, and the gene expression levels (GRCh37; Gencode ver 19) were quantified with the HTSeq package \[[@R35], [@R36]\]. The edgeR package was used to select differentially expressed genes from the RNA-seq count data \[[@R37]\]. Meanwhile, the RPKM value- of each gene was floored to 1, and log2-transformed for further analysis (heatmap and correlation analysis). All RNA sequencing data were deposited in the public repository (GEO Accession Number: GSE46597). Bam files were available at <http://mgrc.kribb.re.kr/KRIBB/BAM/RNA-seq/RNA-seq.html>.

ChIP-seq and data analysis {#s4_4}
--------------------------

ChIP-sequencing was performed for seven gastric cancer cell lines. A protocol generated at the Myers laboratory (<http://hudsonalpha.org/myers-lab/protocols>) was used with minor modifications. First, seven gastric cancer cell lines were fixed using 1% formaldehyde, lysed and sonicated using a Bioruptor (Diagenode Inc.). Then, 20 μg of H3K27ac antibody was prebound to 100 μl Dynabeads Protein (Life Technologies). For ChIP-sequencing, 250-400 bp genomic libraries were generated from the input and chromatin immunoprecipitated DNA and sequenced using Genome Analyzer IIx or Hiseq-2000 to generate 51 bp or 101 bp single-end reads. The sequencing reads were also aligned to the reference sequence (hg 19) using the BWA software. The results generated by MACS (v.1.4.2) \[[@R38]\] were loaded into the IGV for visualization \[[@R39]\]. PeakAnnotator from Homer (v 4.7) was used to annotate each peak. All ChIP sequencing data were deposited in the public repository (GEO Accession Number: GSE75595). Bam files were available at <http://mgrc.kribb.re.kr/KRIBB/BAM/ChIP-seq/ChIP-seq.html>.

Methylation analyses of distal regulatory regions {#s4_5}
-------------------------------------------------

Promoter regions were defined as 2 kb upstream of TSS to 0.5 kb downstream of TSS. Enhancer regions were defined from H3K27ac ChIP-seq and DNase-seq peaks. First, H3K27ac ChIP-seq peaks were detected by MACS, and each peak from seven gastric cell lines was merged into a total of 363,256 peaks using mergedBed of bedtools (ver. 2.17.0) \[[@R40]\]. Second, DHS peaks were detected by Homer and each peak from 11 gastric tissues was merged into a total 227,413 peaks using mergedBed of bedtools. The intersectBed command in bedtools was used to determine overlapping regions between differentially methylated regions and DHS at active enhancer regions. The targets of enhancer were selected from their nearest promoters on the same chromosome. The correlation between the promoter DNA methylation and expression of each lncRNA was measured with Pearson\'s correlation coefficient in the R-package.

Analysis of subtype-specific methylation {#s4_6}
----------------------------------------

GC methylation and expression data were obtained from the TCGA (available at the <https://tcga-data.nci.nih.gov/tcga/>). Each sample was grouped into four distinct molecular subtypes as defined in \[[@R20]\]. Subtype-specific DMRs were identified by comparing tumors in each subtype and six normal samples. Significance was inferred using Student\'s t-test.

Public data process {#s4_7}
-------------------

Processed DNA methylation (HumanMethylation450k) and expression (mRNA-sequencing) data of stomach adenocarcinomas (STAD) were downloaded from The Cancer Genome Atlas data portal (<https://tcga-data.nci.nih.gov/tcga/>). Clinical and molecular-subtype information was obtained from the TCGA project article \[[@R20]\]. The sample details are described in [Supplementary Data S7](#SD8){ref-type="supplementary-material"}. The DNase-seq data of fetal stomach were downloaded from the Gene Expression Omnibus database (GSE189727). The sample information of the DNase-seq data is described in [Supplementary Table S4](#SD1){ref-type="supplementary-material"}.

Bisulfite sequencing {#s4_8}
--------------------

Genomic DNA (2 μg) from each sample was modified by sodium bisulfite using the EZ DNA methylation kit (Zymo Research), according to the manufacturer\'s instructions, and PCR amplified. The PCR products were cloned into pGEM-T Easy vector (Promega), and several clones were randomly chosen for sequencing. Bisulfite-modified DNA was amplified using primer sets designed to amplify sites +14 to +324 for HNF4A-P1 and -155 to +285 for HNF4A-P2 using MethPrimer (<http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi>). Primer sequences used for HNF4A-P1 were 5′-GGTAGAGAGGGTATTGGGAGGAGGTA-3′ (forward) and 5′-CCCACCCCAAAATTAAATACCAAAA-3′ (reverse). The primer sequences used for HNF4A-P2 were 5′-TATTTTGGGTGATTAGAAGAATTAA-3′ (forward) and 5′-CCTCTACCCCAAAACTTCTC-3′ (reverse).

5-aza-2′-deoxycytidine {#s4_9}
----------------------

Gastric cancer cell lines (KATOIII, MKN1, SNU620, SNU005, SNU016, and AGS) were seeded in 100 mm dishes at a density of 1×10^6^ cells/dish, treated with 10 μM 5-Aza-dC (Sigma-Aldrich) every 24 h for 3 days and then harvested.
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